Table 2.
Targeted therapies for PTCL: Small molecules, antibodies, and immune checkpoint inhibitors targeting molecular pathways
| Small molecules | Inhibitors |
|---|---|
| Vorinostat | Histone deacetylases (HDACs) |
| Romidepsin | |
| Belinostat | |
| Chidamide | |
| Pralatrexate | Dihydrofolate reductase |
| Decitabine (5-aza-2′-deoxycytidine) | DNA methyltransferases |
| 5-aza-cytidine | |
| Duvelisib | PI3 kinases |
| Copanlisib | |
| Tenalisib | |
| Bortezomib | Blocks IκB degradation and NF-κB translocation by targeting 26S proteasome |
| Carfilzomib | 20S proteasome |
| Ixazomib | Proteasome subunit beta type-5 (PSMB5) |
| Everolimus | Targets FK506 binding protein-12 (FKBP-12) inhibiting mTORC1 |
| Crizotinib | Tyrosine kinase receptors: anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR) |
| Antibodies | |
| Mogamulizumab | CCR4 chemokine receptor |
| Brentuximab vedotin | CD30 (TNFRSF8) |
| Hu5F9-G4 | CD47 |
| TTI-621 | |
| Immune checkpoint inhibitors | |
| Nivolumab | PD-L1 |
| Durvalumab | |
| Pembrolizumab | PD-1 |